Catalyst
Slingshot members are tracking this event:
Bristol-Myers Squibb’s Opdivo (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Advanced Form of Bladder Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| BMY |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 27, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Breakthrough Therapy Designation, Phase 2 Study Ca209-275, Bladder Cancer, Urothelial Cancer
